Understanding and targeting abnormal hormone production in prostate cancer without CHD1.
Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancer
This study is looking at how the missing CHD1 gene in prostate cancer affects hormone production and treatment resistance, with the goal of finding new ways to help patients with advanced prostate cancer feel better and respond to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11067794 on NIH RePORTER |
What this research studies
This research investigates how the loss of the CHD1 gene affects hormone production in prostate cancer, leading to resistance against common treatments. It focuses on the role of abnormal androgen synthesis within tumors and how this contributes to the progression of the disease. By examining the interactions between CHD1 and other proteins, the study aims to uncover new therapeutic targets that could improve treatment outcomes for patients with advanced prostate cancer. The approach includes analyzing genetic and biochemical pathways involved in hormone synthesis and resistance mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those with CHD1 gene deletions or resistance to androgen receptor inhibitors.
Not a fit: Patients with early-stage prostate cancer or those whose cancer is not driven by androgen receptor signaling may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced prostate cancer who currently have limited options due to treatment resistance.
How similar studies have performed: Previous research has shown promising results in targeting androgen receptor signaling in prostate cancer, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Domingo-Domenech, Josep Maria — Mayo Clinic Rochester
- Study coordinator: Domingo-Domenech, Josep Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.